On February 3, 2025, BioNTech SE (“BioNTech”) confirmed the completion of its acquisition of biotechnology company Biotheus for an upfront payment of $800 million and up to $150 million in potential milestone payments. Biotheus will operate as an indirect Chinese subsidiary of BioNTech. Under the terms of the agreement, BioNTech…